Clinical trials may constitute use, but when they do not, then there is no justification for non-use, says the CJEU
The concept of genuine use of a trademark should be the same for all sorts of products/services, but for pharmaceuticals this is not always the case. Given the particular regulatory regime which applies to pharmaceuticals, often many years pass before the marketing authorization to any given new pharmaceutical specialty is granted. During that time, do…